Posters & Publications.
Posters
- Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab
SITC - November 2023 - IKF-s614: INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with 1st line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas - a multicenter early phase trial
ESMO - October 2023 - Combining the antigen presenting cell activator eftilagimod alpha (soluble LAG 3) and pembrolizumab: overall survival data from the 1st line non-small cell lung carcinoma cohort of TACTI 002
ESMO - Mini Oral Presentation - October 2023 - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas - EFTISARC-NEO trial
ESMO - October 2023 - Final results from TACTI-002 Part C: A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1
ASCO - June 2023 - AIPAC-003: A randomized, double-blind, placebo-controlled phase 3 trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization
ASCO - June 2023 - Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) & pembrolizumab in 2nd line metastatic NSCLC patients resistant to PD-1/PD-L1 inhibitors ELCC - Mini Oral Presentation - March 2023
- Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)
SITC - Late-Breaking Abstract, Oral Presentation - November 2022 - TACTI-003: A randomized Phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma
SITC - November 2022 - Feasibility of eftilagimod alpha (soluble LAG-3 protein) combined with standard-of-care therapy in advanced non-small-cell lung cancer (NSCLC) adenocarcinomas - Initial results from INSIGHT 003
SITC - November 2022 - Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients
IASLC World Conference on Lung Cancer - August 2022 - A phase II study (TACTI-002) in first-line metastatic non–small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population.
ASCO - Oral Presentation - June 2022 - TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
ASCO - June 2022 - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) to placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast carcinoma.
ESMO - May 2022 - Results from a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma (NSCLC) patients
ELCC - March 2022 - Results from a Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)
SITC (click here for poster with comments) - November 2021 - Final results from AIPAC: A phase IIb trial comparing eftilagimod alpha (soluble LAG-3 protein) in combination with weekly paclitaxel in HR+ HER2- MBC
SITC - Late Breaking Abstract - November 2021 - A Phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients unselected for PD-L1 expression in first line metastatic head and neck squamous cell carcinoma (HNSCC)
SITC - November 2021 - Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors
ESMO - September 2021 - Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced stage solid tumors.
ASCO (click here for poster with comments) - June 2021 - Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
ASCO (click here for poster with comments) - June 2021 - Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
ASCO (click here for poster with comments) - June 2021 - Primary efficacy results from AIPAC: A double-blinded, placebo controlled, randomized multinational phase IIb trial comparing weekly paclitaxel plus eftilagimod alpha (soluble LAG-3 protein) vs. weekly paclitaxel plus placebo in HR-positive metastatic breast cancer patients
SABCS - Spotlight Session Poster Presentation - December 2020 - Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 1st line non-small cell lung carcinoma (NSCLC)
ESMO - September 2020 - Initial results from a Phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer (HNSCC) patients
ESMO - September 2020 - Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities
ESMO - September 2020 - The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumors
ESMO - September 2020 - Open-label, phase I study evaluating feasibility and safety of subcutaneous IMP321 (a soluble LAG-3 protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumor entities: results from stratum D of the INSIGHT platform trial
ASCO - May 2020 - Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
ASCO - May 2020 - Initial results from a Phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab
AACR (poster with comments) - April 2020 - AIPAC (Active Immunotherapy PAClitaxel): A randomized, double blind, placebo-controlled, multinational Phase IIb trial evaluating the efficacy of eftilagimod alpha (a soluble LAG-3 fusion protein) in combination with paclitaxel in hormone receptor-positive metastatic breast cancer
SABCS - December 2019 - Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab
SITC - November 2019 - TACTI-mel: A soluble LAG-3 LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology
World Immunotherapy Congress - October 2019 - TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic NSCLC, or recurrent PD-X refractory NSCLC or with recurrent or metastatic HNSCC receiving the soluble LAG-3 fusion protein eftilagimod alpha in combination with pembrolizumab
ASCO - June 2019 - The "INSIGHT" Trial: Two new strata of an explorative, open-labeled phase I study evaluating the feasibility and safety of subcutaneous IMP321 injections (LAG-3Ig fusion protein, eftilagimod alpha) combined with either standard-of-care drug therapy or PD-L1 inhibition (avelumab) in advanced-stage solid tumor entities.
ASCO - June 2019 - Phase II study of spartalizumab (PDR001) and LAG525 in advanced solid tumors and hematologic malignancies.
ASCO - June 2019 - Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
SITC - Oral Presentation - November 2018 - Results from a Phase I dose escalation trial (TACTImel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma
SITC - November 2018 - Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321) together with pembrolizumab in unresectable or metastatic melanoma
Society for Melanoma Research - October 2018 - Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha), as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): Final results from the run-in phase of a placebo-controlled randomized phase II.
ASCO - June 2018 - Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma.
ASCO - June 2018
Publications
-
Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial Hans Wildiers, Anne Armstrong, Eveline Cuypere, Florence Dalenc, Luc Dirix, Steve Chan, Frederik Marme, Carolina P. Schroder, Jens Huober, Francois P. Duhoux, Peter Vuylsteke, Agnes Jager, Etienne Brain, Sherko Kuemmel, Zsuzsanna Papai, Catharina Willemien Menke-van der Houven van Oordt, Luca Perjesi, Christian Mueller, Chrystelle Brignone, and Frederic Triebel. Clinical Cancer Research, OF1-OF10. https://doi.org/10.1158/1078-0432.CCR-23-1173
- A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology S.-E. Al-Batran, D.W. Mueller, M.-R. Rafiyan, D. Kiselicki, A. Atmaca, T. Habibzada, C. Mueller, C. Brignone, F. Triebel, M. Loose, M. Schaaf, D. Sookthai, R. Eickhoff, E. Jaeger, T.O. Goetze ESMO Open Volume 8, Issue 5, October 2023, 101623
- The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application Jin-Ling Huo, Ya-Tao Wang, Wen-Jia Fu, Nan Lu, Zhang-Suo Liu Front. Immunol., 26 July 2022 Sec. Cancer Immunity and Immunotherapy https://doi.org/10.3389/fimmu.2022.956090
- Clinical landscape of LAG-3-targeted therapy L. Chocarro, E. Blanco, H. Arasanz, L. Fernández-Rubio, A. Bocanegra, M. Echaide, M. Garnica, P. Ramos, G. Fernández-Hinojal, R. Vera, G. Kochan & D. Escors. IOTECH: Immuno-Oncology and Technology Review March 2022
- Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies Schöffski P, Tan DSW, Martín M, et al. Journal for ImmunoTherapy of Cancer January 2022;10:e003776. doi:10.1136/ jitc-2021-003776
- Juvenile idiopathic arthritis: lymphocyte activation gene-3 is a central immune receptor in children with oligoarticular subtypes Erdal Sag, Selcan Demir, Maithri Aspari, Morten Aagaard Nielsen, Cæcilie Skejø, Malene Hvid, Egemen Turhan, Yelda Bilginer, Stinne Greisen, Seza Ozen and Bent Deleuran. May 2021. Pediatric Research
- Depletion of LAG-3+ T Cells Translated to Pharmacology and Improvement in Psoriasis Disease Activity: A Phase I Randomized Study of mAb GSK2831781 Ellis, Marks, Srinivasan, Barrett, Hopkins, Richards, Fuhr et al. May 2021, Clin. Pharmacol. Ther., 109: 1293-1303. https://doi.org/10.1002/cpt.2091
- Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F. J lmmunother Cancer. 2020 Nov; 8(2):e001681.
- Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis Slevin, Garner, Lahiff, Tan, Wang, Ferry, Greenaway et al. October 2020 Journal of Crohn's and Colitis, Volume 14, Issue 10
- A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases. Angin M, Brignone C, Triebel F. J lmmunol. 2020 Feb 15; 204(4):810-818.
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 Qin, Xu, Yi et al. Molecular Cancer (2019) 18:155 https://doi.org/10.1186/s12943-019-1091-2
- P449 Selective depletion of LAG3+ cells in T-cell-driven inflammation: a randomised, double-blind, placebo-controlled, FTIH phase I/Ib clinical trial Ellis, Marks, Barrett, Hopkins, Richards, Fuhr, Albayaty et al. Journal of Crohn's and Colitis, Volume 13, Issue Supplement_1, March 2019, Page S336, https://doi.org/10.1093/ecco-jcc/jjy222.573
- Combination of paclitaxel and LAG-3lg (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II. Duhoux FP, Jager A, Dirix L, Huizing MT, Jerusalem G, Vuylsteke P, De Cuypere E, Breiner D, Mueller, Brignone C and Triebel F. 2017. Journal of Clinical Oncology 35:1062.
- Immunotherapy earns its spot in the ranks of cancer therapy. Pardoll D. and Drake C.. 2012. J Exp Med 209:2.
- Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3+)-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates N Poirier, T Haudebourg, C Brignone, N Dilek, J Hervouet, D Minault, F Coulon, R V de Silly, F Triebel, G Blancho, B Vanhove May 2011 Clinical and Experimental Immunology, Volume 164, Issue 2
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. Brignone, C., M. Gutierrez, F. Mefti, E. Brain, R. Jarcau, F. Cvitkovic, N. Bousetta, J. Medioni, J. Gligorov, C. Grygar, M. Marcu, and F. Triebel. 2010. J Transl Med 8:71.
- A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Brignone, C., B. Escudier, C. Grygar, M. Marcu, and F. Triebel. 2009. Clinical Cancer Research 15:6225.
- A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. Brignone, C., C. Grygar, M. Marcu, K. Schakel, and F. Triebel. 2007. J Immunol 179:4202.
- A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Triebel, F., K. Hacene, and M. F. Pichon. 2006. Cancer Lett 235:147.
- LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Triebel, F. 2003. Trends Immunol 24:619.
- LAG-3 induces tumor regression and antitumor immune responses in vivo. Prigent, P., S. E. Mir, M. Dreano, and F. Triebel. 1999. Eur. J. Immunol. 29:3867.
- Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Huard, B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. Maigret, M. Dreano, and F. Triebel. 1997. Proc. Natl. Acad. Sci. USA 94:5744.
- LAG-3, a novel lymphocyte activation gene closely related to CD4. Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevée, E. Viegas-Pequignot, and T. Hercend. 1990. J.Exp. Med. 171:1393.